Biontech Se

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Biontech Rna Pharmaceuticals Gmbh

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Biontech Rna Pharmaceuticals Gbmh

Tron-Translationale Onkologie An Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Ggmbh

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Martin Löwer

Ugur Sahin

Sebastian Kreiter

John Christopher Castle

Sebastian Boegel

Barbara Schrörs

Michael Koslowski

Mustafa Diken

Tana Omokoko

Jan Diekmann

Bernhard Renard

Johannes Hendrikus De Graaf

Arbel David Tadmor

Cedrik Britten

Mathias Vormehr

Petra Oehm

Martin Suchan

Arbel D Tadmor

The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

Methods for characterizing loss of antigen presentation

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

Individualized vaccines for cancer

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Predicting immunogenicity of T cell epitopes

The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

Predicting T cell epitopes useful for vaccination

Growing community of inventors

Mainz, Germany

Martin Löwer